Detail

Study ID: Alliance A041702

Title:

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region, Thief River Falls
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
CLL (Chronic Lymphocytic Leukemia)
Stage:
Phase III
Status:
Active - Open to Accrual